Microbial Machines utilizes synthetically engineered bacteria to detect and treat diseases affecting the alimentary tract. This technology provides targeted therapeutic solutions, improving patient outcomes by addressing specific gastrointestinal conditions.
Funding
$3.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting and treating diseases in the alimentary tract lack precise targeting, leading to potential side effects and reduced efficacy. Existing therapies often affect the entire gastrointestinal system, rather than focusing on specific areas or conditions.
Solution
Microbial Machines engineers bacteria to act as targeted therapeutic agents within the alimentary tract. By programming these microorganisms, the company creates solutions that can detect specific disease markers and deliver treatments directly to the affected areas. This approach aims to improve patient outcomes by increasing therapeutic efficacy while minimizing off-target effects. The technology offers the potential for personalized treatments tailored to individual gastrointestinal conditions.
Target Audience
The primary target audience includes patients with gastrointestinal diseases, as well as gastroenterologists and medical researchers seeking advanced therapeutic solutions.
Features
- Synthetically engineered bacteria for targeted drug delivery
- Disease marker detection within the alimentary tract
- Programmable microorganisms for customized therapeutic action